Serenity's deeper genetic intelligence
uncovered Maram's medication risks.
Maram, age 46, is of Lebanese descent and has had a heart valve replacement due to an underlying health condition.
Standard genetic testing results alone would have only identified that Maram has a gene variant rs9923231, genotype TT.
Maram knows she has this gene variant but is given no other information. She doesn't know how this relates to her health or medication regimen.
Serenity's expert team uses AI and advanced intelligence to analyze Maram’s gene variant, ethnicity and her heart condition to reveal unique health insights.
Genetic intelligence notifies Maram's doctor that she should receive a lower dose of her medication, acenocoumarol, as she has an increased risk of blood clots. This does adjustment helps to reduce her overall risk of heart attack and stroke.
Serenity's ongoing health updates helped John better
manage his medication dose in real-time.
John, age 42, was diagnosed with depression several years ago
John’s 2017 standard genetic test identified a gene variant rs1045642, genotype A/A.
John’s doctor prescribes him trazodone, an antidepressant, which was considered safe for him. John felt some benefit but still struggled with his depression especially when stressed.
One year later, John became a Serenity member. Serenity provided John with a real-time alert on newly discovered associations between his gene variant and his antidepressant medication.
Serenity shows that John’s body clears his medication more quickly than average. This information prompts John’s doctor to adjust his dose and modify the prescription accordingly. John is now managing his depression better.
Only Serenity identified risks with
Dave’s immunosuppressant medication
following a kidney transplant.
Dave, age 43, has ulcerative colitis (an inflammatory bowel disease) and has recently undergone a kidney transplant. His doctor is considering prescribing azathioprine, an immunosuppressant to prevent organ rejection.
A standard genetics report finds that Dave has a variant rs1127354, genotype C/A.
Dave knows he has a gene variant but the report does not identify any considerations for treatment with azathioprine.
Serenity reveals that Dave’s gene variant has been associated with decreased metabolism of azathioprine, specifically in patients with inflammatory bowel diseases.
Dave’s doctor sees this warning and prescribes a lower dose of azathioprine to avoid harmful side effects like severe bruising, bleeding, and overall weakness. Dave is feeling better and his doctor is monitoring him more closely.
Serenity’s real-time health updates protected Susan from
potential adverse effects of her pain medication.
Susan, age 51, suffers from severe chronic pain due to an injury. She previously took a Serenity test.
Initial Serenity Finding
Genetic testing identifies a gene variant rs2740574, genotype TT.
Susan’s doctor decided to prescribe buprenorphine (an opioid partial antagonist) to treat the pain long-term at a standard dose.
New Serenity Discovery
Serenity provided Susan with a real-time update regarding her gene variant and pain medication.
New studies had found an association between Susan’s variant and increased response to buprenorphine in people with pain. Susan’s doctor decides to lower her dose of buprenorphine to manage her risk of overdose and developing a dependency on her medication.